158 related articles for article (PubMed ID: 34042171)
1. Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real-life experience in a tertiary referral centre.
Gallo G; Rostagno E; Siliquini N; Stroppiana E; Verrone A; Ortoncelli M; Quaglino P; Dapavo P; Ribero S
Australas J Dermatol; 2021 Aug; 62(3):e431-e432. PubMed ID: 34042171
[No Abstract] [Full Text] [Related]
2. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.
Lukas M; Malickova K; Kolar M; Bortlik M; Vasatko M; Machkova N; Hruba V; Duricova D; Lukas M
J Crohns Colitis; 2020 Jul; 14(7):915-919. PubMed ID: 31905382
[TBL] [Abstract][Full Text] [Related]
3. Comparable drug levels and immunogenicity in patients with axial spondyloarthritis treated with adalimumab originator and biosimilar: A retrospective study from two centers of China.
Fu ZC; Cheng XG; Zhang GW; Shi RG; Zhang LJ; Sun HT; Huang JX
Int J Rheum Dis; 2024 May; 27(5):e15190. PubMed ID: 38736279
[No Abstract] [Full Text] [Related]
4. GP2017: An Adalimumab Biosimilar.
Heo YA
BioDrugs; 2018 Dec; 32(6):635-638. PubMed ID: 30460599
[TBL] [Abstract][Full Text] [Related]
5. A single-centre, observational, retrospective, real-life study evaluating adalimumab biosimilar ABP 501 in the treatment of plaque-type psoriasis and psoriatic arthritis in originator-naïve patients and in patients undergoing non-medical switch from originator.
Giunta A; Zangrilli A; Bavetta M; Manfreda V; Pensa C; Bianchi L
Curr Med Res Opin; 2021 Jul; 37(7):1099-1102. PubMed ID: 34011212
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars in Inflammatory Bowel Disease.
Buchner AM; Schneider Y; Lichtenstein GR
Am J Gastroenterol; 2021 Jan; 116(1):45-56. PubMed ID: 33110013
[TBL] [Abstract][Full Text] [Related]
7. Switching from Other Biologics to ZRC3197 (Adalimumab Biosimilar) in Patients with Spondyloarthropathy: A Prospective Evaluation from Real-Life Clinical Practice.
Kapoor S
J Assoc Physicians India; 2017 May; 65(5 Suppl):26-29. PubMed ID: 28836748
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, tolerability, and safety of infliximab biosimilar in comparison to originator biologic and adalimumab in patients with Crohn disease.
Kaniewska M; Rosołowski M; Rydzewska G
Pol Arch Intern Med; 2019 Aug; 129(7-8):484-489. PubMed ID: 31316042
[TBL] [Abstract][Full Text] [Related]
9. SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501.
Macaluso FS; Cappello M; Busacca A; Fries W; Viola A; Costantino G; Magnano A; Vinci E; Ferracane C; Privitera AC; Piccillo G; Belluardo N; Giangreco E; Romano C; Citrano M; Graziano F; Garufi S; Bertolami C; Ventimiglia M; Scrivo B; Teresi G; Renna S; Rizzuto G; Casà A; Orlando A;
J Gastroenterol Hepatol; 2021 Nov; 36(11):3041-3049. PubMed ID: 34152636
[TBL] [Abstract][Full Text] [Related]
10. Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice.
Armuzzi A; Bouhnik Y; Cummings F; Bettey M; Pieper B; Kang T
Dig Liver Dis; 2020 Nov; 52(11):1259-1265. PubMed ID: 32601035
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
Nabi H; Georgiadis S; Loft AG; Hendricks O; Jensen DV; Andersen M; Chrysidis S; Colic A; Danebod K; Hussein MR; Kalisz MH; Kristensen S; Lomborg N; Manilo N; Munk HL; Pedersen JK; Raun JL; Mehnert F; Krogh NS; Hetland ML; Glintborg B
Ann Rheum Dis; 2021 Nov; 80(11):1400-1409. PubMed ID: 33926921
[TBL] [Abstract][Full Text] [Related]
12. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
JAMA Dermatol; 2021 Jun; 157(6):676-683. PubMed ID: 33825804
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
14. Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis.
Ruda RC; Kelly KA; Feldman SR
J Dermatolog Treat; 2023 Dec; 34(1):2140569. PubMed ID: 36305624
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis: a single center study.
Ricceri F; Rosi E; Di Cesare A; Scandagli I; Fastame MT; Prignano F
J Dermatolog Treat; 2022 Jun; 33(4):1983-1985. PubMed ID: 33929274
[TBL] [Abstract][Full Text] [Related]
16. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
Crosby M; Tadrous M; Gomes T
Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
[TBL] [Abstract][Full Text] [Related]
17. Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis.
Murray GM; Griffith N; Sinnappurajar P; Al Julandani DA; Clarke SLN; Hawley DP; Choi J; Guly CM; Ramanan AV
Ocul Immunol Inflamm; 2024 May; 32(4):442-446. PubMed ID: 36803373
[TBL] [Abstract][Full Text] [Related]
18. Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis.
Renton WD; Leveret H; Guly C; Smee H; Leveret J; Ramanan AV
Pediatr Rheumatol Online J; 2019 Oct; 17(1):67. PubMed ID: 31585539
[TBL] [Abstract][Full Text] [Related]
19. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Clin Rheumatol; 2018 May; 37(5):1199-1205. PubMed ID: 29392511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
